In a world where biotech startups burn millions before a single patient sees a molecule, Oncurie is operating in pure stealth mode. With just 4 employees and a domain that literally has zero monthly visits, they're generating nearly $1M in revenue. This isn't a typo—it's a masterclass in B2B biotech sales where websites don't matter.

"They're building a radiopharmaceutical empire while their website remains a ghost town—because in biotech, the real deals happen in conference halls, not on landing pages."

The radiopharmaceutical space is exploding—Lilly's $1.4B acquisition of Point Biopharma and Novartis's $1B deal for Mariana Oncology prove it. Oncurie sits in this exact sweet spot, likely developing targeted alpha therapy or next-gen PET imaging agents. With zero digital footprint, they're either in stealth pre-clinical stages or they've built a business model that doesn't require public-facing marketing.

• Revenue-first approach: $0.8M with minimal burn
• Ultra-lean team: 4 people managing entire pipeline
• Zero digital dependency: No SEO, no content, pure B2B
• Strategic silence: No social profiles, no press releases
• Domain authority: Oncurie.com ranks for 'prana curie' organically